Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
TECHNIVIE (OMBITASVIR; PARITAPREVIR; RITONAVIR) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
TECHNIVIE
NDA
Get alerts
OMBITASVIR; PARITAPREVIR; RITONAVIR | N207931 | ABBVIE INC
1 strength
6 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
6 unique patents by expiration date
Active (6)
Today
PED (+6 mo)
2027
2028
2029
2030
2031
2032
Today
8420596
Oct. 10, 2031
8642538
Sep. 10, 2029
8686026
Jun. 9, 2031
8691938
Apr. 13, 2032
9006387
Jun. 10, 2030
9044480
Apr. 10, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
6 patents
0 exclusivities
▴
TABLET;ORAL | Approved: Jul 24, 2015
Patents (6)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8420596
Apr 10, 2031
PED: Oct 10, 2031
PED
Yes
Yes
—
—
8642538
Sep 10, 2029
—
Yes
Yes
U-1638
TREATMENT OF HCV INFECTION USING PARITAPREVIR
—
8686026
Jun 9, 2031
—
—
Yes
—
—
8691938
Apr 13, 2032
—
Yes
Yes
—
—
9006387
Jun 10, 2030
—
—
—
U-1687
TREATMENT OF HCV INFECTION USING OMBITASVIR
—
9044480
Apr 10, 2031
—
—
—
U-1638
TREATMENT OF HCV INFECTION USING PARITAPREVIR
—